Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been recently diagnosed with multiple myeloma for the first time, and whose doctor has determined they are not suitable for high-dose chemotherapy and stem cell transplantation.
- People who have a score of 1 or higher on a standard myeloma frailty scale used to assess overall health and vulnerability (the IMWG Myeloma Frailty Index).
- People whose myeloma can be measured through recent blood or urine tests, showing enough disease activity to be tracked — specifically, detectable levels of certain proteins in the blood or urine within the past 28 days (confirm with trial site for exact test results required).
Who may not be able to join:
- People who have previously received, or are currently receiving, any systemic treatment or stem cell transplant for multiple myeloma or a related blood condition — except for a short course of steroids.
- People who have received an experimental treatment within the past 30 days (or longer, depending on the treatment), or who are currently enrolled in another clinical trial.
- People whose multiple myeloma has spread to the brain or spinal cord.
- People who have had a significant health problem affecting the kidneys, nervous system, mental health, hormones, immune system, lungs, or liver within the past 6 months, where the doctor believes this could negatively affect participation in the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s; Phase 2: Change in Clinical Activity; Phase 3: Minimal Residual Disease (MRD) Negative CR Rate; Phase 3: Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.